Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACI-RX vs BACIGUENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
FDA-approved: Treatment of superficial skin infections caused by susceptible organisms,Off-label: Ophthalmic infections (conjunctivitis, blepharitis), nasal carriage of Staphylococcus aureus
Topical treatment of superficial skin infections caused by susceptible strains of Staphylococcus spp., Streptococcus spp., and other gram-positive bacteria,Prophylaxis of minor skin infections,Off-label: Prevention of infection in minor cuts, scrapes, and burns
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 m L/min.
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Bacitracin is not systemically absorbed after topical administration; no significant hepatic metabolism. Systemic absorption can occur with large topical doses or use on denuded skin, and it is excreted primarily unchanged by the kidneys.
Bacitracin undergoes minimal systemic absorption via topical application; not significantly metabolized; excreted unchanged in urine if absorbed.
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Approximately 10-20% bound to serum proteins (albumin).
Approximately 20–30% bound to serum proteins, mainly albumin
0.25-0.4 L/kg. Low Vd indicates distribution primarily to extracellular fluid; minimal tissue penetration except renal cortex.
0.25–0.4 L/kg (total body water); limited tissue distribution, primarily extracellular fluid
Intramuscular: ~100% (rapid and complete); oral: negligible (<1%) due to poor absorption; topical: variable, minimal systemic absorption (<5% with intact skin).
Topical: negligible systemic absorption (<0.5%) through intact skin; oral: not absorbed (inactivated in GI tract; not used systemically)
No adjustment required; bacitracin is not significantly renally eliminated.
No dose adjustment required for topical use; systemic absorption is minimal.
No adjustment required; bacitracin is not hepatically metabolized.
No dose adjustment required for topical use.
Weight-based dosing as per standard protocol: 1-2 units/kg intramuscularly every 2-4 hours; adjust based on factor levels.
Apply thin layer to affected area 1 to 3 times daily; safety in infants under 2 months not established.
Use standard dosing with caution for renal function; assess GFR and adjust if impaired.
No specific dose adjustment; use same as adult dosing.
No FDA black box warning.
Due to nephrotoxicity, bacitracin is NOT recommended for parenteral use; topical use only.
Nephrotoxicity with systemic absorption; avoid use on large surface areas or deep wounds; hypersensitivity reactions; potential for superinfection; not for ophthalmic use unless specifically formulated.
Hypersensitivity reactions including anaphylaxis,Prolonged use may result in overgrowth of non-susceptible organisms, including fungi,Avoid contact with eyes,Not for use on deep wounds or severe burns
Hypersensitivity to bacitracin or any component of the formulation; severe renal impairment (if systemic absorption is possible).
Hypersensitivity to bacitracin or any component of the formulation
No known food interactions with topical bacitracin.
No known food interactions with topical bacitracin. Avoid ingestion.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.
Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contraindicated due to nephrotoxicity, and limited data exist for systemic use in pregnancy. Animal studies show no evidence of harm, but human data are insufficient.
Unknown if excreted in human milk; M/P ratio not available. Caution is advised; consider temporary discontinuation of breastfeeding or drug based on importance to mother.
Bacitracin is not systemically absorbed from topical use; therefore, breast milk exposure is negligible. M/P ratio is not applicable. Considered safe during breastfeeding when used topically. For systemic use, avoid due to potential nephrotoxicity.
No dose adjustment required due to pregnancy-related pharmacokinetic changes; dose based on indication and renal function.
No dosing adjustment needed for topical bacitracin. Systemic use is contraindicated in pregnancy due to risk of maternal nephrotoxicity; if unavoidable, use with extreme caution and monitor renal function, but no specific dose recommendations exist.
BACI-RX (bacitracin) is a topical antibiotic effective against gram-positive organisms. Avoid systemic use due to nephrotoxicity. Apply thin layer; hypersensitivity reactions possible. Not for ophthalmic use unless specified. Monitor for superinfection with prolonged use.
Bacitracin is a topical polypeptide antibiotic effective against gram-positive organisms. It is often combined with neomycin and polymyxin B in triple antibiotic ointments. For minor wounds, apply a thin layer 1-3 times daily. Avoid use on large body surface areas or for deep puncture wounds due to risk of systemic absorption and nephrotoxicity. Monitor for allergic contact dermatitis, especially with prolonged use.
Apply a thin layer to affected area as directed.,Wash hands before and after application unless treating hands.,Do not use on large areas of skin or deep puncture wounds.,Stop use and consult provider if rash or irritation develops.,Do not use in eyes or mouth unless specifically prescribed.,Store at room temperature away from moisture and heat.
Clean the affected area before each application.,Apply a thin layer of ointment 1 to 3 times daily.,Do not use on large areas of the body, deep wounds, or animal bites.,Stop use and consult a doctor if the condition worsens or does not improve within 1 week.,Avoid contact with eyes or mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACI-RX vs BACIGUENT, answered by our medical review team.
BACI-RX is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.. BACIGUENT is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACI-RX and BACIGUENT depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACI-RX is: 1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.. The standard adult dose of BACIGUENT is: Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACI-RX and BACIGUENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACI-RX is classified as Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.. BACIGUENT is classified as Category C. Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contrai. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.